ANZCTR search results

This study aims to evaluate the feasibility and impact of incorporating a stereotactic ablative radiotherapy (SABR) boost before definitive radiotherapy in the treatment of muscle-invasive bladder cancer (MIBC). Who is it for? You may be eligible for this study if you are a male or female, aged 18 or over, and diagnosed with muscle-invasive urothelial carcinoma of the bladder (T2-4a) of any grade. You need to be suitable for radical radiotherapy and medically inoperable or refused to undergo radical cystectomy. Study details Participants will be given SABR dose escalation of 8-10Gy in 1 single session prior to standard course of radiotherapy with or without chemotherapy. During and after the intervention, participants will be assessed for disease free survival of bladder cancer using Computer Tomography imaging of pelvis and cystoscopy examinations. Acute and late toxicities will be assessed using the grading of the National Cancer Institute Common Toxicity Criteria for Adverse Events v5.0 It is hoped that this research will improve local disease control in patients with muscle-invasive bladder cancer by evaluating the feasibility and effectiveness of incorporating a stereotactic ablative radiotherapy (SABR) boost prior to standard definitive radiotherapy.

RespectED is a universal school-based prevention program designed to reduce harmful attitudes and behaviors related to intimate partner violence (IPV) among adolescents. Delivered through five 40-minute cartoon-based lessons during Year 9/10 health education classes, the program aims to challenge attitudes condoning violence and build skills for healthy relationships. We hypothesise that students who participate in respectED will have lower rates of harmful attitudes condoning dating violence, as well as reduced IPV victimisation and perpetration, compared to students in the control condition at 6-month follow-up.

The SMART-AF study will enroll patients with atrial fibrillation, half randomly assigned access to a digital tracking platform to help participants engage and track their progress with optimal RFM for atrial fibrillation, half randomised to control. The aim of this study is to investigate the effiacy of a digital tracking platform to help participants engage, track and meet their progress towards optimal RFM, and it's relationship with AF outcomes.

DALE is a prospective, multi-site registry and biorepository, established to facilitate the collection of clinical data and biospecimens with the aim of furthering drug allergy research. Research questions which may be addressed relate to the epidemiology of drug allergy, our mechanistic understanding of the immune response to drugs in allergic patients, predictors of true or false drug allergy, diagnostic methods to identify causative drugs and quality of care in the management of drug allergy and delabelling.

This will be a double-blind, multicenter, parallel arms study of low and high dose levels of BRP-180 evaluated for improving wakefulness and reducing cataplexy in patients with Type 1 Narcolepsy. This trial will consist of 3 study periods: 1. Screening and Observation Period: Day -42 to Day 0. Sleepiness and cataplexy diary recording daily. 2. Treatment Period: Weeks 1-8. Parallel arms treatment period. During the treatment period, patients self-administer the allocated treatment (low doses of BRP-180, high doses of BRP-180, or placebo) once a day for 8 consecutive weeks.Sleepiness and cataplexy diary recording. 3. Follow-up Period: Week 9-12. Continued sleepiness and cataplexy diary recording daily and bi-weekly telehealth check-ins

It is hypothesised that there will be a correlation between the overall exposure to vancomycin of the whole blood (as represented by drawn serum samples) and subdermal tissue (as represented by ISF concentrations measured by the Nutromics device). This study is to assess the validity of this hypothesis in healthy human subjects, as a precursor to studies in the Device’s intended use population. It is designed to be able to deconvolute within participant effects from between participant effects, by giving multiple different doses to the same participants and repeating over multiple participants.

Online symptom checkers are digital health tools allowing health consumers to input symptoms to receive triage or diagnosis advice. If appropriate, another important feature is to provide consumers with self-care advice for managing their symptoms at home. Integrating Generative Artificial Intelligence (AI) into symptom checkers may help address unmet needs of diverse users, including those with lower health literacy. A retrieval-augmented generation (RAG) framework may be particularly useful by addressing concerns around accuracy via greater control of the quality of information informing the AI output. However, it is unknown how to best communicate the use of RAG generative AI in symptom checkers, nor how to present the advice. This project aims to 1) evaluate the effects of different presentations of generative AI symptom checker self-care advice on intentions, trustworthiness and understanding of the advice, and 2) explore in-depth user responses and perspectives on AI generated triage and self-care advice in an online symptom checker.

This will be a Phase 1, single center, comparative bioavailability, open-label, randomized, single-dose, 2-period, crossover study to evaluate the relative bioavailability of 2 formulations of GT-02287 in healthy adult participants. Participants will receive a single oral dose (10 mg/kg of GT-02287) of each formulation, in fasting conditions, in a crossover fashion during 2 periods.

The primary aim of this project is to evaluate the effectiveness of accessible cervical screening information for people supporting people with intellectual disability to make an informed decision about whether to have a cervical screening test. Who is it for? You may be eligible for this study if you area family member or support person (unpaid or paid, for example, disability support worker or family carer) of a person/people with intellectual disability who are eligible for screening in the National Cervical Screening Program. Study details: Participants will receive a link to a website with accessible cervical screening information, including Easy Read information and videos about the Cervical Screening Test, and resources to support communication about the test with people with intellectual disability and healthcare providers. They will have access to these resources for four months. Participants will be asked to complete a short survey before and after accessing these resources. It is hoped that the findings of this study will help us to improve access to and experiences of cervical screening amongst people with intellectual disability.

The primary aim of this project is to evaluate the effectiveness of online training for healthcare providers to support their cervical screening practice for people with intellectual disability. Who is it for? You may be eligible for this study if you are a GP or nurse working in Australia. Study details: Participants will have access an online training module designed to help them provide better cervical screening for people with intellectual disabilities. The training covers topics such as the importance of cervical screening, communication strategies, and managing consent. They will have access to this training for four months. Participants will be asked to complete a short survey before and after accessing the training. It is hoped that the findings of this study will help us to improve access to and experiences of cervical screening amongst people with intellectual disability.